|
【结 构 式】 
|
【分子编号】61404 【品名】(2S)-1-{(2S,5S,8S,11S,14R,17S)-11-[(1R)-1-(tert-butoxy)ethyl]-2-{3-[(imino{[(2,2,5,7,8-pentamethyl-3,4,4a,8a-tetrahydro-2H-chromen-6-yl)sulfonyl]amino}methyl)amino]propyl}-17-isopropyl-24-methyl-5,14-bis[(1S)-1-methylpropyl]-4,7,10,13,16,19,22,25-oc 【CA登记号】 |
【 分 子 式 】C64H111N13O14S 【 分 子 量 】1318.73056 【元素组成】C 58.29% H 8.48% N 13.81% O 16.99% S 2.43% |
合成路线1
该中间体在本合成路线中的序号：(XX)Coupling of resin (XVI) with N-Fmoc-sarcosine (XVII), followed by treatment with piperidine, provides (XVIII). This is treated with acetic acid and HBTU, producing the N-acetylated peptide resin (XIX). Cleavage of (XIX) from the resin in the presence of ethylamine leads to the side-chain protected peptide amide (XX).
| 【1】 Haviv, F.; Kalvin, D.M.; Henkin, J.; Bradley, M.F.; Schneider, A.J. (Abbott Laboratories Inc.); Peptide antiangiogenic drugs. JP 2002516342; WO 9961476 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (XVI) | 61401 | (2S)-1-{(2S,5S,8S,11S,14R,17S)-20-amino-11-[(1R)-1-(tert-butoxy)ethyl]-2-{3-[(imino{[(2,2,5,7,8-pentamethyl-3,4,4a,8a-tetrahydro-2H-chromen-6-yl)sulfonyl]amino}methyl)amino]propyl}-17-isopropyl-5,14-bis[(1S)-1-methylpropyl]-4,7,10,13,16,19-hexaoxo-8-propyl-3,6,9,12,15,18-hexaazaicos-1-anoyl}-2-pyrrolidinecarboxylic acid | C57H99N11O13S | 详情 | 详情 | |
| (XVII) | 52441 | 2-[{[(9H-fluoren-9-ylmethyl)oxy]carbonyl}(methyl)amino]acetic acid | C18H17NO4 | 详情 | 详情 | |
| (XVIII) | 61402 | (2S)-1-{(2S,5S,8S,11S,14R,17S)-11-[(1R)-1-(tert-butoxy)ethyl]-2-{3-[(imino{[(2,2,5,7,8-pentamethyl-3,4,4a,8a-tetrahydro-2H-chromen-6-yl)sulfonyl]amino}methyl)amino]propyl}-17-isopropyl-5,14-bis[(1S)-1-methylpropyl]-4,7,10,13,16,19,22-heptaoxo-8-propyl-3,6,9,12,15,18,21,24-octaazapentacos-1-anoyl}-2-pyrrolidinecarboxylic acid | C60H104N12O14S | 详情 | 详情 | |
| (XIX) | 61403 | (2S)-1-{(2S,5S,8S,11S,14R,17S)-11-[(1R)-1-(tert-butoxy)ethyl]-2-{3-[(imino{[(2,2,5,7,8-pentamethyl-3,4,4a,8a-tetrahydro-2H-chromen-6-yl)sulfonyl]amino}methyl)amino]propyl}-17-isopropyl-24-methyl-5,14-bis[(1S)-1-methylpropyl]-4,7,10,13,16,19,22,25-octaoxo-8-propyl-3,6,9,12,15,18,21,24-octaazahexacos-1-anoyl}-2-pyrrolidinecarboxylic acid | C62H106N12O15S | 详情 | 详情 | |
| (XX) | 61404 | (2S)-1-{(2S,5S,8S,11S,14R,17S)-11-[(1R)-1-(tert-butoxy)ethyl]-2-{3-[(imino{[(2,2,5,7,8-pentamethyl-3,4,4a,8a-tetrahydro-2H-chromen-6-yl)sulfonyl]amino}methyl)amino]propyl}-17-isopropyl-24-methyl-5,14-bis[(1S)-1-methylpropyl]-4,7,10,13,16,19,22,25-oc | C64H111N13O14S | 详情 | 详情 |
合成路线2
该中间体在本合成路线中的序号：(XX)The side-chain O-tert-butyl and N-pentamethylchromansulfonyl protecting groups of peptide (XX) are finally removed by treatment with trifluoroacetic acid in the presence of thioanisole and ethanedithiol to furnish the deprotected peptide, which is then purified by preparative HPLC.
| 【1】 Haviv, F.; Kalvin, D.M.; Henkin, J.; Bradley, M.F.; Schneider, A.J. (Abbott Laboratories Inc.); Peptide antiangiogenic drugs. JP 2002516342; WO 9961476 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (XX) | 61404 | (2S)-1-{(2S,5S,8S,11S,14R,17S)-11-[(1R)-1-(tert-butoxy)ethyl]-2-{3-[(imino{[(2,2,5,7,8-pentamethyl-3,4,4a,8a-tetrahydro-2H-chromen-6-yl)sulfonyl]amino}methyl)amino]propyl}-17-isopropyl-24-methyl-5,14-bis[(1S)-1-methylpropyl]-4,7,10,13,16,19,22,25-oc | C64H111N13O14S | 详情 | 详情 |